Mar 03,2021

Blue Note Therapeutics Raises $26.25 Million in Series A Financing

Blue Note Therapeutics, Inc., today announced the closing of a Series A financing round of $26.25 million. Proceeds will allow the company to scale the organization and fund near-term clinical trials of its lead prescription digital therapeutic (PDT), which will potentially improve the treatment of cancer. The capital will also support the development of Blue Note's pipeline assets. The Series A financing was led by JAZZ Venture Partners and joined by Summer VC.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Apr 20,2021

VieCure Announces $25 Million Series A Investment Led by Northpond Ventures to Improve Oncology Care, Scale A.I. and Patient-focused Technologies

VieCure, Inc. today announced the closing of its $25 million Series A growth equity investment, led by Northpond Ventures. An undisclosed investor is also contributing to the round. VieCure, an oncology clinical informatics company with an artificial intelligence (AI) enabled clinical decision support platform, will use the new funding to accelerate the deployment of its next generation clinical decision support solution, and grow the sales and business development organization in response to the expanding pipeline and partnering opportunities in the life sciences arena. Andrea Jackson, Director for Northpond Ventures, will join the new VieCure Board of Directors.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Apr 22,2021

BGF invests $12m in virtual oncology business Entia

Entia, a medical technology business, which recently announced a commercial partnership with Pfizer UK, raised $12 million earlier in the year in a funding round co-led by UK growth capital investor, BGF and growth fund manager, Parkwalk, with participation from existing seed investor Sussex Place Ventures.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Apr 28,2021

Outcomes4Me Raises $12M in Series A Funding Round

Outcomes4Me Inc., a Cambridge, Mass.-based developer of an Artificial Intelligence (AI)-powered platform to empower cancer patients to navigate their care, raised $12m in Series A funding round.The round was led by Northpond Ventures, with participation from all existing investors, including Sierra Ventures, Asset Management Ventures, Merstal Ltd, IRA Capital, and others. Andrea Jackson, a Northpond Ventures Director, will join Outcomes4Me�s board. The company intends to use the funds to extend its platform beyond breast cancer to other cancers, grow the platform�s regulatory-grade dataset, and expand to more patients in Europe

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Sep 09,2021

Blue Note Therapeutics Raises $5.2M in Additional Series A Funding

Blue Note Therapeutics raised an additional $5.2 million in Series A financing, bringing the company�s Series A financing to a total of $31 million. The financing was provided by Memorial Sloan Kettering cancer center (MSK) and Alumni Ventures who joined Series A lead investors JAZZ Venture Partners and Summer VC. The additional proceeds will strengthen Blue Note�s capacity to develop evidence-based therapeutics that serve an increasing number of cancer patients.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Sep 20,2021

Digital chronic care company Wefight raises $11.7 million

This morning Wefight, a French digital health company focused on guiding patients with chronic conditions and cancer through their care, scored $11.7 million (�10 million). Digital Health Ventures, Impact Partners, the Business Angels of the BADGE network, MELIES Business Angels, Investir&+, and Angels Sant� participated in this round of funding. This comes roughly two years after the company closed a �1.8M seed funding round in 2019. The company has created a slew of patient-facing apps that use an artificial intelligence chatbot dubbed Vik to help answer patients� questions. The company is looking to expand its geographical footprint in Europe and internationally. On the product side, the company said the funds will be put towards offerings regarding more diseases.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Jan 24,2022

CUREETY, the French start-up specialized in data and remote-monitoring in oncology, raises €5 million

CUREETY, the leading remote-monitoring start-up in the field of digital oncology, announced that it has raised five million euros in funding. This financing round was led by French health insurance companies with the support of Cureety's existing investors, bank pool and the public investment bank bpifrance. The transaction coincides in France with the new Social Security financing law allowing for the reimbursement of remote-monitoring solutions starting in 2022.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Jan 25,2022

Reimagine Care Secures $25 Million in Series A Funding to Drive Commercialization of Home-Centered, Value-Based Cancer Care

Reimagine Care, an innovative provider of technology-enabled services that supports oncologists in delivering high-quality, home-centered, value-based cancer care, today announced it has completed a $25 million capital raise led by Sante Ventures, Martin Ventures, and LRVHealth. The funding will be leveraged to further develop and commercialize the company's first-of-its kind technology-enabled services platform, launch the virtual care center, and expand the patient care team. Several strategic investors joined the financing round including the CU Healthcare Innovation Fund, a strategic healthcare fund affiliated with the University of Colorado Anschutz Medical Campus; City of Hope, a National Cancer Institute-designated comprehensive cancer center and founding member of the National Comprehensive Cancer Network; McKesson Ventures; and Sable Investments.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Feb 04,2022

£5m for AI cancer detection platform C the Signs

C the Signs has raised £5 million of investment to move closer to its mission to create a future where every patient survives cancer. It hopes the investment from MMC, Ataraxia and Acequia Capital, alongside notable angels including the past CEO of AXA Health, past CEO of Bupa and founder of Monzo, will be transformative in driving forward plans to scale the impact of the technology to accelerate early cancer detection and survival. The firm was founded by two NHS doctors, Dr Bea Bakshi and Dr Miles Payling, following the loss of a patient due to a delayed cancer diagnosis.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Mar 17,2022

Canopy raises $13 million to improve oncology practices

Canopy, which develops an Intelligent Care Platform (ICP) for oncology, announced on Thursday that it has raised $13 million in funding led by GSR Ventures, with participation from Samsung Next, UpWest, and other industry leaders and executives, such as Geoff Calkins (former SVP Product, Flatiron Health), and Chris Mansi (CEO Of Viz.AI). Formerly known as Expain, Canopy will use the funding to make its platform generally available to cancer treatment centers across the U.S., and recruit 40 additional employees for its R&D center in Israel, which currently employs 30 people

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Subscribe to SERIES A